Showing results (541-550 of 9,400) with videos related to
Sort By:
Pageof 940
Clinical Pharmacology and Therapeutics|June 18, 2005
Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population studyRasmus Steen Pedersen, Per Damkier, Kim BrosenClinical Pharmacology and Therapeutics|May 1, 1992
Exercise alters the pharmacokinetics of midazolamC Strömberg, J Vanakoski, K T Olkkola, et al.Clinical Pharmacology and Therapeutics|May 1, 1992
Alprazolam in end-stage renal disease. II. PharmacodynamicsV D Schmith, B Piraino, R B Smith, et al.Clinical Pharmacology and Therapeutics|May 1, 1992
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placeboM Weintraub, P R Sundaresan, M Madan, et al.Clinical Pharmacology and Therapeutics|May 1, 1992
Long-term weight control study. VII (weeks 0 to 210). Serum lipid changesM Weintraub, P R Sundaresan, B SchusterClinical Pharmacology and Therapeutics|October 4, 2006
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulationSara Colombo, Thierry Buclin, Laurent A Décosterd, et al.Clinical Pharmacology and Therapeutics|October 4, 2006
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinMikko Niemi, Marja K Pasanen, Pertti J NeuvonenClinical Pharmacology and Therapeutics|October 4, 2006
MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquineAlbert L H J Aarnoudse, Ron H N van Schaik, Jeanne Dieleman, et al.Clinical Pharmacology and Therapeutics|October 4, 2006
Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosisYasunori Kaneshiro, Yutaka Oda, Kentaro Iwakiri, et al.Clinical Pharmacology and Therapeutics|October 4, 2006
Human pharmacology of the methamphetamine stereoisomersJohn Mendelson, Naoto Uemura, Debra Harris, et al.Pageof 940